Evidence map›Paper›PMID 26769798›Full record

ArticleDisease models & mechanisms2016

5-HT2A and 5-HT2C receptors as hypothalamic targets of developmental programming in male rats.

Malgorzata S Martin-Gronert, Claire J Stocker, Edward T Wargent, Roselle L Cripps, Alastair S Garfield, Zorica Jovanovic, Giuseppe D'Agostino, Giles S H Yeo, Michael A Cawthorne, Jonathan R S Arch and 2 more

Open access · goldAbstract read
In one paragraph

Article in Disease models & mechanisms, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Gestational Factors throughout Fetal Neurodevelopment: The Serotonin Link.International journal of molecular sciences · 2020
    Review
  9. Article
  10. Review
  11. Glucagon-Like Peptide-1 (GLP-1) and 5-Hydroxytryptamine 2c (5-HTInternational journal of molecular sciences · 2019
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. A RATional choice for translational research?Disease models & mechanisms · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Malgorzata S Martin-GronertUniversity of Cambridge, Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK msm32@cam.ac.uk.
Claire J StockerClore Laboratory, Buckingham Institute for Translational Medicine, University of Buckingham, Hunter Street, Buckingham MK18 1EG, UK.
Edward T WargentClore Laboratory, Buckingham Institute for Translational Medicine, University of Buckingham, Hunter Street, Buckingham MK18 1EG, UK.
Roselle L CrippsUniversity of Cambridge, Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Alastair S GarfieldDepartment of Pharmacology, University of Cambridge, Cambridge CB2 1PD, UK.
Zorica JovanovicUniversity of Cambridge, Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Giuseppe D'AgostinoDepartment of Pharmacology, University of Cambridge, Cambridge CB2 1PD, UK.
Giles S H YeoUniversity of Cambridge, Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Michael A CawthorneClore Laboratory, Buckingham Institute for Translational Medicine, University of Buckingham, Hunter Street, Buckingham MK18 1EG, UK.
Jonathan R S ArchClore Laboratory, Buckingham Institute for Translational Medicine, University of Buckingham, Hunter Street, Buckingham MK18 1EG, UK.
Lora K HeislerDepartment of Pharmacology, University of Cambridge, Cambridge CB2 1PD, UK.
Susan E OzanneUniversity of Cambridge, Metabolic Research Laboratories and MRC Metabolic Diseases Unit, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
University of Cambridge · GBUniversity of Buckingham · GBAddenbrooke's Hospital · GBWellcome/MRC Institute of Metabolic Science · GB

Funding

Biotechnology and Biological Sciences Research Council BB/E007821/1Biotechnology and Biological Sciences Research Council BB/E00797X/1Biotechnology and Biological Sciences Research Council BB/K001418 /1Biotechnology and Biological Sciences Research Council E007821/1Biotechnology and Biological Sciences Research Council E00797X/1British Heart Foundation FS/09/029/27902Medical Research Council MC_UU_12012/1Medical Research Council MC_UU_12012/4Medical Research Council MC_UU_12012/5Wellcome Trust 081713Wellcome Trust 098012Wellcome Trust WT081713
6 · The paper itself

Abstract

Although obesity is a global epidemic, the physiological mechanisms involved are not well understood. Recent advances reveal that susceptibility to obesity can be programmed by maternal and neonatal nutrition. Specifically, a maternal low-protein diet during pregnancy causes decreased intrauterine growth, rapid postnatal catch-up growth and an increased risk for diet-induced obesity. Given that the synthesis of the neurotransmitter 5-hydroxytryptamine (5-HT) is nutritionally regulated and 5-HT is a trophic factor, we hypothesised that maternal diet influences fetal 5-HT exposure, which then influences development of the central appetite network and the subsequent efficacy of 5-HT to control energy balance in later life. Consistent with our hypothesis, pregnant rats fed a low-protein diet exhibited elevated serum levels of 5-HT, which was also evident in the placenta and fetal brains at embryonic day 16.5. This increase was associated with reduced levels of 5-HT2CR, the primary 5-HT receptor influencing appetite, in the fetal, neonatal and adult hypothalamus. As expected, a reduction of 5-HT2CR was associated with impaired sensitivity to 5-HT-mediated appetite suppression in adulthood. 5-HT primarily achieves effects on appetite by 5-HT2CR stimulation of pro-opiomelanocortin (POMC) peptides within the arcuate nucleus of the hypothalamus (ARC). We show that 5-HT2ARs are also anatomically positioned to influence the activity of ARC POMC neurons and that mRNA encoding 5-HT2AR is increased in the hypothalamus ofin uterogrowth-restricted offspring that underwent rapid postnatal catch-up growth. Furthermore, these animals at 3 months of age are more sensitive to appetite suppression induced by 5-HT2AR agonists. These findings not only reveal a 5-HT-mediated mechanism underlying the programming of susceptibility to obesity, but also provide a promising means to correct it, by treatment with a 5-HT2AR agonist.

Indexed as

Growth and DevelopmentAnimalsAnimals, NewbornArcuate Nucleus of HypothalamusBody WeightDietary ProteinsFeeding BehaviorFemaleFenfluramineFetusHypothalamusLaser Capture MicrodissectionMaleNeuronsOligonucleotide Array Sequence AnalysisOrgan SizeDietary ProteinsFenfluramineReceptor, Serotonin, 5-HT2AReceptor, Serotonin, 5-HT2CSerotoninTryptophanDevelopmental programmingHypothalamusLow birth weightMaternal dietProtein restrictionSerotonin

Identifiers

PMID26769798
PMCPMC4852506
OpenAlexW2281749991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.